Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.49 |
| ▸ | HTR1D | P28221 | 10/20 | 0.49 |
| ▸ | HTR1B | P28222 | 10/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179690 | 0.85 | HTR1A (0.51) | HTR1AHTR1DHTR1BACHE | |
| SCHEMBL6179195 | 0.85 | TP53 (0.44) | ACHEBCHEHTR6 | |
| SCHEMBL6180465 | 0.83 | HTR1A (0.59) | HTR1AHTR1DHTR1B | |
| SCHEMBL6181255 | 0.82 | PDE10A (0.45) | ACHEHTR6 | |
| SCHEMBL6179764 | 0.79 | HTR2C (0.51) | HTR1AHTR1DHTR1BHTR6 | |
| SCHEMBL6370415 | 0.78 | BCHE (0.40) | ACHEBCHEHTR6 | |
| SCHEMBL1255986 | 0.76 | ACHE (0.59) | ACHEKITGRIA1GBA1 | |
| SCHEMBL16647038 | 0.75 | CNR1 (0.53) | HTR1AHTR1DHTR1BACHEKIT | |
| SCHEMBL17844999 | 0.74 | KIT (0.49) | HTR1AHTR1DHTR1BACHEKIT | |
| SCHEMBL21594139 | 0.74 | ACHE (0.51) | ACHEKITTLR9TLR7GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | HTR1A 2/4885HTR1D 3/4885HTR1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.